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ABSTRACT 
Tumor suppressor genes (TSGs) or oncogenes aberrantly methylated in transcription 
control regions during early carcinogenesis are potential tools for early detection of 
cancer. We have identified suitable genes and explored assays based on their 
methylation status aiming for early detection of cancer: nasopharyngeal carcinoma 
(NPC) and non-small cell lung cancer (NSCLC).  
We established and developed further the “multiplex methylation specific-PCR 
(MMSP)” assay designed to detect the tumor-specific methylation status of several 
NPC-related genes (paper I). It provided information about the methylation status of 
multiple genes simultaneously in a single PCR with small amounts of tumor DNA 
derived from nasopharyngeal swabs. It was shown to be applicable with DNA from as 
few as 10 cells. The detection rate of NPC from nasopharyngeal swabs was 98%. The 
false positive rate was zero. 
We employed the MMSP assay on NPC tumors from two other regions (Morocco and 
Italy) and compared our results with those on Chinese NPC patients from paper I 
(paper II). We also did a pilot study using sera from Italian and Chinese NPC. We 
updated the panel of MMSP markers and modified the assay to improve its 
applicability to NPC from different geographical locations. We could detect at least 
any one methylation marker gene in 97% of the EBNA1 positive samples with a 
specificity of 94%, while the results on sera were less informative than using swabs.  
We used an established NotI microarray method to identify gene losses (by deletion or 
methylation) in chromosome 3 of NPC tumors (paper III), This chromosome is 
known to contain TSGs involved in many cancer types. Ten candidate TSGs were 
found. Among them, the CpG rich area in the promoter region of Integrin α9 (ITGA9) 
was confirmed to be hypermethylated in NPC by bisulfite cloned sequencing, bisulfite 
pyrosequencing and methylation specific PCR. ITGA9 was downregulated in NPC 
clinical samples and 5-aza-2′-deoxycytidine restored the expression of ITGA9 in NPC 
derived cell lines. The functional role of ITGA9 downregulation in NPC should be 
explored further.  
We developed an MMSP assay for analysis of the methylation status of multiple 
potential TSGs in NSCLC samples (paper IV). Thirty-eight potential TSGs were 
selected, based on literature search, genome-wide CpG methylation and expression 
microarrays performed on NSCLC tissues and matched control tissues. After 
evaluation by methylation specific PCR (MSP) six of these genes were selected for 
inclusion into the MMSP assay. Subsequently, 70 NSCLC DNA samples with 
matched controls and 24 non-cancerous DNA samples were screened with this assay. 
With a cut off of methylation of at least any two of these marker genes 87% of the 
cancer samples were detected with a specificity of 94%. Early stage I or II NSCLC 
showed a 100% specificity and 86% sensitivity. 
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1 INTRODUCTION 
1.1 General introduction to cancer 
Cancer is one of the leading causes of death globally.1 It claimed 8.2 million human 
lives in 2012 while an estimated 14 million new cases of cancer were diagnosed in 
the same year.2 It has been estimated that the number of new cases may rise by about 
70% over the next 20 years.1 The most common cancer related deaths globally are 
lung, liver, stomach, colorectal, breast and esophageal cancer.2 There are dramatic 
differences in the incidence of specific cancer types between different geographic 
regions. 
Tumorigenesis is a multistep process that reflects genetic alterations driving the 
progressive transformation of normal human cells into highly malignant tumor cells. 
The resulting abnormal cells grow rapidly, do not respect their usual boundaries and 
thus may invade adjoining parts of the body and spread to other distant body organs. 
This spreading process of cancer is known as metastasis. Metastases are the main 
cause of deaths from cancer irrespective of the part the body from where cancer 
actually originated. 
1.1.1 Cancer etiology 
Cancer is thought to be initiated from a single cell. A normal cell undergoes multiple 
stages on its way to a cancer cell. This is also characteristic of the progression from a 
pre-cancerous lesion into a malignant tumor.  
Tumorigenesis is the outcome of interplay between the genetic make-up of individual 
and different types of external carcinogens. These external carcinogenic factors can 
be categorized into four main types: physical carcinogens (e.g. ultraviolet and 
ionizing radiation); chemical carcinogens (e.g. asbestos, components of tobacco 
smoke, food and water contaminants, e.g. aflatoxin, arsenine); biological carcinogens 
(e.g. certain viruses, bacteria or parasites) and general life style factors (e.g. diet). Use 
of tobacco, alcohol consumption, unhealthy diet, obesity and physically inactive life 
are some common leading cancer risk factors worldwide.1 Aging is another important 
factor in cancer development. The risk of cancer development increases with age.1 
This depends on the time needed for the multistep tumor progression, but also due to 
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an accumulation of risk exposures with age combined with less effective cellular 
repair mechanisms and immune defense at an older age. 
1.1.2 Cancer control strategies 
Reduction in global cancer incidence and mortality is only possible by implementing 
evidence-based approaches for cancer prevention, early detection and better treatment. 
Early diagnosis of cancer is the first step to better cancer management and its treatment. 
The majority of cancer patients are diagnosed at an advanced stage of the disease. Late 
diagnosis of cancer is a major reason for cancer related deaths worldwide. In case of 
late diagnosis, the chances of survival are lower because the disease is already at an 
advanced stage and the risk of metastatic spread is larger. Another reason for the high 
cancer mortality is lack of efficient treatments, particularly for advanced stages. Early 
detection of cancer is important for efficient treatment and thus is one key to reduce 
cancer related deaths. Early detection of cancer is also very relevant in the absence of 
cancer screening programs in low-resource settings.1 
1.1.3 Hallmarks of cancer 
It was suggested that the genetic changes, that are common to most types of cancers, 
may be grouped into ten essential alterations in cell physiology that collectively 
dictate malignant growth, designated as the hallmarks of cancer.3, 4 These hallmarks 
are presented schematically in figure 1. When acquired as physiological capabilities 
they make tumor cells resistant to defense mechanisms of the normal cell and the 
host.3, 4  
 
Figure 1. The hallmarks of cancer. Cited from Hanahan and Weinberg 2011.4 
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1.1.4 Multistage nature of cancer initiation and development 
It has been suggested that tumor development proceeds like a Darwinian evolutionary 
process during which a sequence of genetic changes, each which results in the 
selective survival advantage and sequential acquisition of tumor properties by the cell 
– a process commonly referred to as tumor progression. Four to seven such changes 
in the genome are considered the minimum requirement to develop many types of 
cancers. The model for multistage development of colorectal cancer was the first and 
so far still the best well defined, suggested by Fearon and Vogelstein in 1990 (Figure 
2).3  
 
Figure 2. Fearon and Vogelstein's model for the initiation and development of colorectal 
carcinoma. The development of colorectal carcinoma is a multistep process in which genetic and 
epigenetic alterations accumulate in a sequential order where every step gives a growth advantage to 
the cancer cells.   
According to this model the colorectal carcinoma develops through a multistep 
process in which genetic and epigenetic alterations accumulate in a sequential (linear) 
order and result in the loss of tumor suppressor genes (TSGs) and aberrant activation 
of oncogenes affecting multiple pathogenic pathways.5, 6 The resulting deregulated 
expression of TSGs and oncogenes were thought to be behind the continued clonal 
selection and heterogeneity of the tumor cells.5 In line with this model the earlier 
changes during the course of cancer development could be a potential useful 
screening tool for colorectal carcinoma.7 
1.2 Epigenetic mechanisms of gene regulation and their role 
in tumorigenesis 
Historically, the word “epigenetics” was first coined by Conrad Waddington in 1942 
to describe events that were not justifiable by genetic principles. According to him 
epigenetics is the branch of biology which deals with the study of causal connections 
between genes and their products that give rise to the phenotype.8 The increase in 
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molecular understanding of genome functions has demanded a refinement of the 
definition of epigenetics. Now epigenetics refers to heritable alterations of phenotype 
that are independent of DNA sequence, but still reversible.9-11 In principle cells in a 
multicellular organism share the same genotype but during cellular differentiation 
attain different phenotypes, distinct profiles of gene expression and cellular functions. 
This was first proposed by Waddington in 1957 (Figure 3).12 Thus epigenetics is a 
bridge between genotype and phenotype as they can be brought about by exogenous, 
environmental factors and thus may modify the phenotype by its bridging between 
genome and the environment.11, 13  
 
Figure 3. Waddington's classical epigenetic landscape. Cited from Waddington 1957.12 
Epigenetic alterations play a major role in a vast array of biological functions during 
normal development and growth.14-19 Epigenetic mechanisms are associated with the 
suppression of the large number of transposable and retroviral elements in the 
mammalian genome.20-22 Epigenetic aberrations also contribute to pathological 
conditions,23 such as cancer24, 25 and disorders of the immune,26 endocrine,27 and 
nervous systems.28  
Epigenetic alterations can act as an alternative to mutations in the process of 
tumorigenesis. Now it has been well established that epigenetic alterations are 
essential not only for the progression but also in the initiation process preceding the 
first mutations (Figure 4).29   
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Figure 4. Genetic versus epigenetic models of cancer. (A) The classical monoclonal genetic model of 
cancer. (B) The epigenetic progenitor model of cancer. Cited from Feinberg et al. 2006.29 
Epigenetic mechanisms of gene regulation involve semi-reversible covalent chemical 
modifications of DNA bases and the proteins with which DNA is associated in the 
nucleus of the cell.30 These mechanisms include DNA methylation, histone 
modification, but also noncoding RNAs and chromatin remodeling associated gene 
silencing.11 Some of the aberrantly expressed genes involved in epigenetic 
modifications in tumor cells are listed in table 1.  
Table 1. Some epigenetic modifier genes in human cancer. 
Gene Change Cancer Refs 
IGF2 Increased Colorectal, gastric and breast cancers 31-33 
HDACs Increased Several cancers 34-42 
EZH2 Increased Prostate and breast cancers 43, 44 
KATs Decreased Several cancers 37 
SIRT1 and SIRT3 Increased Prostate and breast cancers 45, 46 
KDM5C Increased Breast cancer 47 
SMYD3 Increased Liver, colon and breast cancers 48 
EHMT1 Decreased Medulloblastoma 49 
DNMT1 and DNMT3B Increased Pancreas, liver, bladder and breast cancers 50-54 
AID Increased Leukaemia 55 
AID: activation-induced cytidine deaminase; DNMT: DNA methyltransferase; EHMT1: euchromatic 
histone-lysine N-methyltransferase 1; EZH2: enhancer of zeste homologue 2; KAT: lysine 
acetyltransferase; HDAC, histone deacetylase; IGF2: insulin-like growth factor 2; KDM5C: lysine-
specific demethylase 5C; SIRT: sirtuin; SMYD3: SET and MYND domain-containing 3. 
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1.2.1  DNA methylation  
DNA methylation is the most extensively studied epigenetic mark. In mammals it 
occurs primarily by the covalent addition of a methyl group on the 5-carbon of 
cytosine residues in cytosine–guanine (CpG) dinucleotides that may result in the 
suppression of gene expression (Figure 5).  
 
Figure 5. Cytosine methylation. (A) Methylation of cytosine in CpG dinucleotides, catalyzed by 
DNMTs, in the presence of SAM. (B) Genes with unmethylated CpGs (white) within their promoter are 
expressed. The methylation of CpGs in the CpG island results in the downregulation of these genes. 
Adopted and modified.56, 57 
DNA methylation plays a significant role during normal mammalian development by 
affecting a vast range of biological functions, such as genomic imprinting,14 cell 
differentiation,16, 58 progression through cell division checkpoints,17 DNA repair,18 X-
chromosome inactivation.19 It is also associated with the prevention of chromosomal 
instability by suppression of massive number of transposable elements20, 59, 60 and 
inactivation of retroviral elements in the mammalian genome.21, 22, 61 Aberrant DNA 
methylation contributes to pathological conditions,23 such as cancer.24, 25 
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1.2.1.1 CpG rich regions in the genome 
Regions rich in of CpG dinucleotides are called CpG islands (CGIs). There is no 
standard definition of CGI but usually the regions of DNA that contain more than 
50% GC content with an observed to expected CpG ratio of greater than 60% (which 
is significantly higher than the average in non-CGI sequence, due to the general CpG 
suppression).62 They are several hundred bases long and there are around 27 thousand 
CGIs within the human genome.63 In humans, 50-70% genes are associated with at 
least one CGI.60, 64, 65 CGIs are primarily located close to promoter regions or 
transcription start sites, in enhancer regions, or in repetitive sequences.60, 66-70 CpGs 
are generally free of methylation in normal cells,66 however some CGIs can be 
methylated during differentiation and in some tissues which results in the 
transcriptional silencing of their associated genes.68, 71, 72 Tissue specific methylated 
DNA regions that are up to 2kb away from CGIs have also been discovered and are 
known as CpG shores.73 The location of different CpG contexts within the human 
genome and their most common methylation status in normal cell genomes are 
illustrated in figure 6. 
 
Figure 6. Distribution of CpG dinucleotides in the human genome. The location of CpG dinucleotides 
within the genome and their methylation status in normal human cells. 
1.2.1.2 DNA methyltransferases 
DNA methyltransferases (DNMTs) are the enzymes involved in the methylation 
process. DNMTs catalyze the methylation of mammalian genomic DNA together with 
some co-factors, such as the polycomb proteins. S-adenosyl-methionine (SAM) serves 
as a methyl donor during this process.74 Five types of DNMTs have been reported in 
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mammals i.e. DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L. A schematic 
representation of these DNMTs is shown in figure 7.  
DNMT1 is the most abundant DNA methyltransferase. It is involved in the 
maintenance of DNA methylation during DNA replication. It is found abundantly at the 
replication fork and methylates newly synthesized daughter strand DNA.75, 76 DNMT2 
is the smallest DNMT and does not have the regulatory N-terminal region. Instead of 
DNA, DNMT2 methylates RNA.77, 78 DNMT3A and DNMT3B function as de novo 
methyltransferases.79, 80 DNMT3L lacks a DNA binding domain in its C-terminal 
domain and thus lacks any DNA methylation capacity but functions as a regulatory 
factor for DNMT3A and DNMT3B by increasing their potential to bind to the methyl 
group donor, SAM.80, 81 The precise role of DNMT3L still needs to be determined.  
 
Figure 7. Schematic representation of human DNMTs. The N-terminal contains motifs of interaction 
with proteins or DNA. The C-terminal contains the catalytic methyltransferase domains. PHD: Plant 
homology domain. Adopted and modified from Subramaniam et al. 2014.76 
1.2.1.3 Demethylation of DNA: 
DNA methylation is a reversible process. It is still controversial how active 
demethylation in specific sites can be achieved. Most likely it is via the enzymatic 
removal of the methyl group from the fifth carbon of the cytosine residue.82 The ten-
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eleven translocation (TET) dioxygenase family of enzymes oxidizes the methyl group 
on 5-methylcytosine (5mC) and converts it to 5-hydroxymethylcytosine (5hmC). The 
further series of oxidation reactions of 5hmC by TETs ultimately leads to the base 
pair excision repair completing the demethylation of 5mC (Figure 8).83-85  
 
Figure 8. Modification of 5-methyl cytosine (5mC). 5mC is oxidized into 5hmC with the catalytic 
effect of TETs in the presence of alpha-ketoglutarate (α KG), O2, ATP and Fe2+. Similar oxidation 
reactions then further modify 5hmC into 5fC and 5CaC. Adopted from Liyanage et al. 2014.86 
1.2.1.4 DNA methylation and gene expression 
DNA methylation can result in down regulation of a gene by direct interference with 
transcription; recruitment of repressive protein complexes; and/or by interacting with 
histone modifying mechanisms (Figure 9).86 DNA methylation may also play an 
indirect role in chromatin remodeling through core histone modification and linker 
histone occupancy and thereby making transcriptional machinery less accessible to 
the methylated gene. The interdependent nature of DNA methylation and chromatin 
compaction has been reported.87, 88 Methylation of CpGs in gene body does not affect 
transcription as the RNA polymerases can read through 5mCs.  
Some proteins, such as methyl-CpG-binding domain (MBD) have increased binding 
affinity to methylated DNA. MBD family of proteins act as insulators for 
transcription factor binding89 and includes MeCP2,90, 91 MBD1,92, 93 MBD2,94 
MBD395 and MBD4.96 MeCP2 has been reported to bind to methylated DNA and 
repress transcription of genes such as Sst, Oprk1, and Mef2c by preventing the 
binding of transcription activator CREB1 to its target site. Transcriptional activation 
of 85% of such genes has been shown in MeCP2 null mice.97  
One example of DNA methylation based interference with transcription is the 
impairment of the binding preference of DNA methylation sensitive transcription 
factor Gli-type transcription factor YY1 to methylated over unmethylated target 
sequences. Gli-type transcription factor YY1 controls the paternal expression 
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of Peg3.98 In in vitro experiments, the methylation of a key CpG site present in the 
YY1-target region in Peg3 can prevent the binding of YY1.98 It has also been 
reported that repression of transcription is not the only mechanism through with DNA 
methylation can exert its affect. But more interestingly some of the transcription 
factors, like zinc finger family transcription factor Kaiso and ZFP57, have been 
reported to have a possible preference for methylated promoter sites and thus in these 
cases DNA methylation can also enhance transcription.99 In short, although DNA 
methylation is mostly a repressive mark, in some cases it can also positively regulate 
the transcription.100 
 
Figure 9. DNA methylation and gene expression. (A) Transcription factors that are sensitive to 
methylated DNA (like YY1) would not facilitate the transcription if the template is methylated; (B) 
MBD proteins (like MeCP2) can bind on methylated DNA and prevent the binding of transcription 
factors to DNA; (C) methylated DNA can be compacted by the action of chromatin remodeling 
enzymes and thereby hampering the access of transcription factors to the DNA. Cited from Zhang and 
Pradhan 2011.100 
1.2.1.5 DNA methylation and tumorigenesis 
Aberrant alterations in DNA methylation (global hypomethylation and CGI 
hypermethylation) were the first epigenetic events discovered in cancer cells.101 The 
role of DNA methylation in cancer is now well established.102-104 Aberrant 
hypermethylation of CGIs in cancer results in the downregulation of TSGs whereas 
the global genome hypomethylation leads to genomic instability and re-expression of 
genes that are silenced in the normal cells.105, 106 Kalari and Pfeifer coined the concept 
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of “driver” and “passenger” DNA methylation modifications in cancer. DNA 
hypermethylation of TSG promoters was referred to as a driver event because of their 
obvious carcinogenic effects. Whereas DNA hypermethylation without any effect on 
cell transformation was designated a passenger hypermethylation events.107 These 
aberrant changes in DNA methylation during carcinogenesis have been attributed to 
abnormality and/or imbalance of DNA demethylating TETs and DNA methylating 
DNMTs.76, 108 The aberrant hypermethylation of promoter CpG-rich regions of TSGs 
in a variety of malignancies is attributed to DNMT3A, DNMT3B and DNMT3L.76 
DNMT1, 3A, and 3B are overexpressed in several human cancers, such as colon,109 
prostate,110 breast, 111 liver,112 and in leukemia.113  
1.2.2 Histone modification 
 DNA is wrapped around a core of histone proteins. A series of epigenetic 
modifications of histones often can change the structure of chromatin and thus 
interfere with the access of various cellular factors to DNA (Figure 10).114, 115 So far 
more than 100 distinct histone modifications have been identified. The most 
important histone modifications are acetylation and methylation of the histones. Other 
histone modification mechanisms include serine/threonine phosphorylation, ADP 
ribosylation, glycosylation, ubiquitination, sumoylation etc.115, 116 The mechanisms and 
the effects of certain histone modifications still need to be established.117  
1.2.2.1 Histone acetylation 
The presence of acetyl groups in histones was first reported in 1963.118 
Hyperacetylated histones were then reported to be associated with highly transcribed 
genes that suggested that histone acetylation could be involved in facilitating gene 
transcription.119, 120 Acetylation occurs on lysine resides on N-terminal tail of the core 
histone proteins and is catalyzed by lysine acetyltransferases (KATs), whereas 
histone deacetylases (HDACs) remove the acetyl group from the histone lysine.121 
Acetylation and deacetylation of histone lysines influence chromatin remodeling and 
in this way regulate the access of transcription machinery to the DNA.122 Histone 
acetylation has also been suggested to play some role in DNA replication123, 124 and 
repair in case of double-strand breaks.125 
Aberrant histone acetylation or deacetylation may lead to up- or down-regulation of 
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gene expression in cancer. The overexpression of HDACs has been reported in 
various cancers.39, 126, 127 The KATs have also been reported to play an important role 
in tumor development e.g. in leukemia.128, 129 
 
Figure 10. Chromatin structure of active and inactive promoter. (A) A transcriptionally active 
chromatin is structurally open and unmethylated at its cytosines, trimethylated at H3K4 and 
hyperacetylated at histones H3 and H4 at multiple sites. (B) Methylated cytosines bind MBDs that attract 
HDACs that in turn remove acetyl groups (Ac) from H3 and H4. Trimethylation of H3 at lysine 9 
(H3K9me3) results in closed chromatin that is a repressive state. Methylated cytosines serve as docking 
sites for MBD proteins such as MeCP2.25, 130  
1.2.2.2 Histone methylation  
Histone methylation may either activate or deactivate transcription. This depends 
upon the amino acid methylated. Unlike acetylation, methylation of a lysine does not 
neutralize its positive charge that indicates an indirect effect of lysine methylation on 
nucleosome dynamics and transcription.131, 132 Histone methylation can also occur on 
arginines,133 but the effects of this modification is still unclear. Methylated lysine 4 and 
36 (H3K4me and H3K36me) are considered to be activation marks whereas 
methylated lysine 9 and 27 (H3K9 and H3K27) are thought to be repression marks of 
transcription (Figure 10). The active histone methylation marks (H3K4me3 and 
H3K36me3) are considered to have an indirect regulatory function. It has been 
suggested that H3K4me3 may exert its activation effect by inhibition of H3K27me3 
methylation.134, 135 The other active histone mark i.e. H3K36me3 has been reported to 
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regulate the histone deacetylation by the catalytic activity of Rpd3S lysine deacetylase 
complex as it has been reported that a recruited Rpd3S remains inactive in the absence 
of H3K36me3.136 Rpd3S complex prevents histone turnover by deacetylating 
histones.137 This is why H3K36me3 is considered to be involved in nucleosome 
stabilization. Another mechanism through which H3K36me3 stabilizes nucleosomes is 
chromatin remodeling, as it enhances the affinity of the repressive Isw1b chromatin 
remodeling complex.138, 139 The inactive histone marks (methylated H3K9 and H3K27) 
are associated with a compact chromatin structure known as heterochromatin formation 
and the silencing of polycombs respectively. H3K9me and H3K27me are also 
suggested to be involved in nucleosome stabilization. Methylation of H3K9 and H3K27 
increases the affinity of certain protein modules for histone residues. H3K9me and 
H3K27me bind chromodomains of HP1 and polycomb respectively. A methylated 
lysine residue can be associated with one, two or three methyl groups. The increase in 
the number of methyl groups on these residues affects nucleosome stabilization.140, 141  
Several factors are supposed to be involved in the number of methyl groups attached 
to a specific lysine residue. Differences in the degree of accessibility and exposure 
time of a histone methyltransferase enzyme to a given lysine residue affects its 
methylated state. For example H2BK123ub1 promotes H3K4me3 and H3K79me3,142 
because histone ubiquitynation modifies the chromatin conformation and increases 
the access of H3K4 to its modifying enzyme. Similarly, histone methyltransferases 
can modify a given lysine in distinct state of methylation depending upon the stability 
of the nucleosome. The more stable the nucleosome, the more methyl groups can be 
attached to a specific lysine by modifying enzymes.143, 144  
1.2.2.2.1 Histone methylation and cancer 
Widespread changes in histone methylation patterns have been observed in cancer. 
Any aberrant change in the active histone methylation can result in the activation of 
genes that could lead to tumor development e.g. it has been reported that chromosomal 
translocations of H3K4 methylating enzyme MLL plays an important role in the 
development of leukemia.145 Altered methylation patterns of H3K9 and H3K27 result 
in aberrant gene silencing in various cancers.146, 147 Deregulation of histone 
methyltransferases (HMTs) leads to aberrant silencing of TSGs. For example, 
overexpression of H3K27 methylating EZH2 has been reported in breast and prostate 
cancer.147 The H3K9 methylating enzyme G9a is overexpressed in liver cancer.126, 148  
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1.2.3 Non-coding RNAs 
Non-coding RNAs (ncRNAs) are transcribed from the DNA but are not translated into 
proteins. These are functionally active in another way than transfer RNAs (tRNAs) and 
ribosomal RNAs (rRNAs) and can repress or activate gene expression. ncRNAs are 
involved in the modulation of various biological processes such as cell division, 
differentiation and apoptosis and are also involved in the development of various 
diseases.100, 149 Non-coding RNAs can be classified on the basis of their size into long 
ncRNAs (lncRNAs) and small ncRNAs (sncRNAs).  
1.2.3.1 Long non-coding RNAs 
Long non-coding RNAs are longer than 200 nucleotides149 and are without any open 
reading frame (ORF).150 lcnRNAs are involved in various biological processes such 
as cell differentiation, organ development, and disease progression.151 They can 
regulate the gene expression at the epigenetic, transcriptional and post-transcriptional 
levels.152 They can interfere in the gene transcription by direct interference with the 
transcription process, in chromatin remodeling by recruiting chromatin modifying 
enzymes, or by forming a triplex structure and silencing the targeted rRNA by 
promoter methylation recruiting the DNA methylating enzyme DNMT3b.153 
Aberrant expression of lncRNAs is reported in various cancers with both oncogenic 
and tumor suppressive functions.154 HOX antisense intergenic RNA (HOTAIR) was 
the first lncRNA identified to be involved in tumorigenesis. HOTAIR is deregulated 
in a number of cancers.155-158 Its expression in breast cancer was reported to be 
upregulated which leads to enhanced repressive activity of polycomb repressor 
complex 2 (PRC2).155 Activated PRC2 causes modifications in histone structure and 
down regulates the expression of target genes.159 MALAT1 is another such oncogenic 
lncRNA that is upregulated in several cancers.160-164  
1.2.3.2 Small non-coding RNAs 
Small non-coding RNAs (sncRNAs) may range between ∼18-27 nucleotides. Micro 
RNAs (miRNAs) are an abundant class of sncRNAs that are also the most well 
studied. In the updated miRBase database, 35,828 mature miRNAs were recently 
registered across all the species (http://mirbase.org, Release 21, accessed June 
2014).165 miRNAs are ∼22 nucleotides long and are transcribed by RNA polymerase II 
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pri-miRNA which are then processed to form the RNA-induced silencing complex 
(RISC). In the RISC complex, miRNAs act as a probe and cleaves the mRNAs that are 
partially complementary to the miRNA. This results in transcriptional silencing of the 
targeted gene.166, 167 It is estimated that miRNAs target ~50% of human genes,168 and 
are involved in almost every biological process. These are also associated to the 
pathogenesis of several diseases.168-170 
miRNAs were first reported to be associated with tumorigenesis in 2002 where 
miRNA-15 and miRNA-16 were reported to be deleted or down-regulated in 68% B-
cell chronic lymphocytic leukemia cases.171 miRNAs can be tumor suppressors and 
oncogenes. Aberrant expression of miRNAs has been associated with the 
development of a number of human cancers.172-174 For example, a cluster made by 
miRNA-15a, miRNA-16-1 and DLEU2 regulates B cell proliferation by targeting 
multiple oncogenes and their deletion results in the development of chronic 
lymphocytic leukemia.175, 176 miRNA-34 in coordination with p53 suppresses prostate 
cancer.177  
1.2.4 Chromatin remodeling 
Epigenetic modifications play an important role in biological processes by affecting 
the chromatin structure and its organization.114 Approximately two meters long DNA 
present in each human cell is compacted 10,000- to 20,000-fold as a nucleosomal fiber 
(chromatin) and in higher-order chromatin structures in the cell nucleus that is only 
∼6 µm in diameter. This is comparable to put 40 km long thin thread into a tennis 
ball.178, 179 The packaging of genome in its three-dimensional spatial structure also 
affects gene expression. Through this mechanism, an enhancer element that could be 
located at a long distance (cis interactions) or even on different chromosomes (trans 
interactions) could affect gene expression.  
A key factor that organizes the genome in its 3D spatial structure is CCCTC-binding 
zinc finger factor CTCF (Figure 11).88 The CCTF mediates both cis and trans 
interactions by forming multiple distinct sections of chromosome, i.e. transcriptional 
harbors.88 CCTF can modulate the chromatin structure through different 
mechanisms.180 For example, CCTF associated transcriptional harbors are enriched in 
active histone methylation signatures (H3K4 and H3K36) which are otherwise enriched 
with inactive histone methylation marks (H3K9, H3K20, and H3K27).88 It has been 
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reported that chromosomes are dynamically packaged at larger than a mega base scale 
but still the actively transcribed genes are made accessible to the transcriptional 
machinery by the establishment of chromosomal boundaries.181 Chromatin remodeling 
is important in the regulation of gene expression. It is also associated with cancer 
development.182 
 
Figure 11. Three-dimensional chromatin interaction. CTCF–cohesin complexes (green) link CTCF 
binding sites in the cis thus contract chromatin fibers. CTCF–cohesion complex may also interact with 
some other unknown factors for long-range interactions within the same chromatin or between 
different chromosomes (light and dark blue). Cited from Ohlsson et al. 2010.180 
1.2.5 Cross-talk between epigenetic mechanisms and tumorigenesis 
Different epigenetic mechanisms extensively cross-talk to each other to maintain and 
regulate the complex transcriptional network in cells. For example, the epigenetic 
processes of DNA methylation/demethylation and chromatin modifications are 
reported to interact with each other.183 The go-betweens during such interactions are 
proteins that bind to the proteins involved in these epigenetic modifications. For 
instance, histone H3 trimethylated at lysine 4 (H3K4me3) binds to recruit tumor 
suppressor inhibitor of growth protein 1b (Ing1). Ing1 interacts with growth arrest and 
DNA damage protein 45a (GADD45a).184 The function of GADD45 in turn is to 
facilitate DNA demethylation of specific genes by recruiting DNA repair enzymes.185 
The H3K4me3 also recruits KATs that results in an increased level of histone 
acetylation and reduced level of 5mC in the nucleosome.186, 187 Another example of 
the cross-talk between different epigenetic mechanisms could be the frequent 
silencing of miRNAs expression by promoter hypermethylation in various cancers.188, 
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189 For example miR-34b/c has been reported to be hypermethylated in lung cancer190, 
191 and chronic lymphocytic leukemia.192 
 
Figure 12. A model for the cross-talk between different epigenetic mechanisms in normal versus 
cancer cells. In normal cells, low-level of double-stranded RNAs are transcribed from hypermethylated 
repetitive DNA. This results in recruitment of the repressive epigenetic machinery (RNAi, DNMTs, 
MBDs). CpG islands (CGIs), in normal cells, are hypomethylated and the associated potential TSGs 
are transcribed. Binding of CTCF inhibits the methylation of these CGIs. In cancer cells, genome-wide 
hypomethylation results in increased genomic instability as it disrupts normal transcription of TSGs by 
generation of ncRNA, recruitment of the RNAi machinery, transcriptional interference and aberrant re-
expression of BORIS that displaces CTCF from CGI which results in its hypermethylation by DNMTs. 
In cancer aberrant changes can occur in all the epigenetic mechanism of gene 
regulation. For example, the genome-wide hypomethylation that occurs particularly at 
repetitive DNA sequences could result in the production of antisense transcripts and 
non-coding RNAs (ncRNAs) and the recruitment of the RNA interference (RNAi) 
machinery (Figure 12). This results in the establishment of repressive epigenetic marks, 
such as DNA methylation, histone modifications and chromatin remodeling at these 
sites. All these epigenetic changes interact with each other and result in the cancer 
initiation and progression.  
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1.3 Introduction to nasopharyngeal carcinoma 
1.3.1 Anatomy and histopathology 
Nasopharyngeal carcinoma (NPC) is a tumor that arises from mucosal epithelial cells 
covering the nasopharyngeal surface, mostly within the lateral nasopharyngeal recess, 
a space behind the nose.193 It is significantly different from other cancers of head and 
neck area in its epidemiologic features, etiology, pathogenesis, histological types, 
treatment and prognosis.194 The most recent histological classification of NPC by 
World Health Organization (WHO) was done in 2005. According to this 
classification, NPC is divided into three major types i.e. squamous cell carcinoma 
(SCC), non-keratinizing carcinoma (differentiated or undifferentiated) and basaloid 
squamous cell carcinoma. Squamous cell carcinoma is highly differentiated and 
retains its epithelial growth pattern and keratin filaments. Non-keratinizing 
differentiated carcinoma lacks keratin filaments but retains its epithelial shape and 
growth pattern and in non-keratinizing undifferentiated carcinoma, the cells do not 
produce keratin filaments and also lack their distinctive epithelial growth pattern. 
Basaloid squamous cell carcinoma type of NPC contains a basaloid neoplasm in the 
regions of squamous differentiation. Only a few cases of basaloid squamous cell 
carcinoma have been reported which makes it a clinically less important.195 
1.3.2 Epidemiology and etiology 
NPC has a notable geographical and ethnic distribution.196 It is an uncommon 
malignancy in most countries of the world. In non-endemic areas, such as United 
States and Europe, its incidence and age-adjusted incidence for both male and female 
is less than one per 100,000 persons. Intermediate incidences ranging between 5-
7/100,000 is reported in several Southeast Asian and North African countries such as 
Indonesia, Malaysia, Thailand, Vietnam Kenya, Greenland, Morocco and Sudan. In 
endemic regions (Southern China) the annual average incidence rate is around 
20/100,000.197-199 Its incidence rate has also been reported to be exceeding 30/100,000 
in Sarawak, Malaysia.200 Differences in the incidence of NPC are also reported in 
different ethnic groups living in the same geographical location.199, 201 NPC is more 
prevalent in males as compared to females.2 Its incidence also increases with the 
increase in age. However a bimodal distribution of NPC is also observed in 
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Mediterranean populations and such juvenile cases of NPC accounts for 20% of the 
all NPC cases in this population. 
The incidence of NPC types is not uniform in different geographical regions. 
Squamous cell carcinoma is prevalent in low-incidence regions such as Europe;202 
where non-keratinizing carcinoma is reported to be on a rise.203-205 Non-keratinizing 
undifferentiated carcinoma is the most common type of NPC in regions of high-
incidence regions such as Southern China and accounts for more than 97% of all 
NPC.206 One of the unique features of non-keratinizing undifferentiated carcinoma is 
its close to 100% association with Epstein-Barr virus (EBV).206-208 Familial NPC has 
been linked with susceptibility loci on chromosome 3p 21,209 4p15.1-q12210 and 5p 
13.211 Consumption of certain food items such as salted fish and preserved food 
containing volatile nitrosamines, especially during childhood, are also reported to 
play some role in the etiology of NPC.212-214 These findings suggest the role of 
genetic, ethnic and environmental factors in the etiology of NPC. 
1.3.3 Clinical presentation and diagnosis 
The early diagnosis of NPC is challenging as compared to most other cancers because 
of its non-specific early signs and hidden anatomical site.215 Early symptoms may not 
be frequently recognizable by the physicians. Patients often show a spectrum of 
symptoms. A majority of the patients present with cervical lymphadenopathy. Other 
symptoms may include neck mass, nasal and aural dysfunction, headache, diplopia, 
facial numbness, weight loss and trismus.216-218 Clinical examination includes 
endoscopy, computed tomography (CT) scan and magnetic resonance imaging (MRI). 
Histological examination of nasopharyngeal biopsy is the classical standard for NPC 
diagnosis.219 However, the invasiveness of this method makes it less suitable as an 
early screening method in NPC high-risk population.220 Measurement of EBV viral 
load in serum or plasma has been shown to be useful for diagnosis and monitoring in 
patients affected by NPC. For this purpose, the analysis of EBV-specific antibodies 
such as serum titers of IgA antibodies to viral capsid antigen (VCA), early antigen 
(EA), nuclear antigen (EBNA) and EBV-specific DNAs are being used for screening 
and monitoring the disease in NPC high-risk population. Nevertheless, the sensitivity 
(Sn) and specificity (Sp) of such assays are not satisfactory.221, 222  
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1.3.4 Treatment and prognosis 
NPC is a radiosensitive tumor and radiotherapy is the standard treatment for almost 
all NPC patients without distant metastasis.223, 224 Although more than 70% overall 
survival rates can be expected for stages I and II, treatment outcomes are unsatisfactory 
for advanced-stage NPC when radiotherapy is offered alone.223-226 The vast majority of 
NPC patients (75-90%) are diagnosed with a loco-regionally advanced disease, 
commonly with cervical nodal metastasis.196 Because of chemosensitive nature of NPC, 
concurrent chemo-radiotherapy is the standard treatment for these patients.227, 228 The 
presence of EBV only in tumor cells provides the possibility of targeting EBV-
specific therapy for NPC. Efforts are being made to develop EBV-targeting 
immunotherapeutic or gene therapeutic strategies.229-233 In spite of all these efforts no 
significant improvements could be made in the early diagnosis of NPC. Although NPC 
is sensitive to chemo-radiotherapy the survival rates remained disappointing.234 A 
majority of the NPC patients are still diagnosed late at stage III and IV with a loco-
regionally advanced disease when the five-year survival rate is only 40-60%.235-238 The 
five-year survival rates for NPC patients could be more than 90% if the disease could 
be diagnosed at stage I.215 Metastasis and loco-regional recurrence are the two major 
reasons of failure in NPC treatment.239, 240 
1.3.5 Epigenetic aspect of nasopharyngeal carcinoma 
A large number of identified genes are silenced in NPC by epigenetic mechanisms, 
primarily by aberrant promoter hypermethylation.241-244 Several key TSGs, such as 
p53, mutated in more than 50% of all tumors, and retinoblastoma (Rb) are usually 
wild-type in NPC.241, 245-247 Deregulated expression of p53 in NPC has been linked 
with methylation dependent silencing of a TSG named UCHL1.248 Hypermethylation 
of several other important TSGs such as P16, RASSF1A249, 250 RARβ2, DAPK, DLEC1 
have also been reported in NPC.243, 249-253 Hypermethylation of several TSGs involved 
in fundamental cellular pathways such as apoptosis, DNA repair, tumor invasion and 
metastasis has been reported in NPC.254 Aberrantly methylated genes reported in NPC 
are summarized in table 2. 
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Table 2. List of aberrantly methylated genes in NPC. 
Cancer-related 
process Gene ID 
Chromosomal 
location Function Refs 
Cell cycle 
 CDKN2B 9p21 Cyclin-dependent kinase inhibitor for CDK4 and 
CDK6, a cell growth regulator of cell cycle G1 
progression 
243, 
255-
257 
 p16 9p21 Cell cycle regulation 243, 
255-
258 
 CHFR 12q24.33 Mitotic checkpoint regulator early in G2-M 
transition 
243, 
259 
 BRD7 16q12 Transcriptional regulation, inhibits G1-S transition 260 
 FHIT 3P14.2 Cell-cycle regulation, G1-S phase checkpoint, 
DNA-damage response, nucleotide and nucleic 
acid metabolism 
261 
 GADD45G 9q22 Inhibits G1-S and G2-M transition, apoptosis 262 
 DLEC1 3p22- 21.3 G1 cell cycle arrest 252 
 ZMYND10 3P21.3 Cell cycle 263 
 MIPOL1 14q13.1 Negative regulator of G1 progression 264 
 PRDM2 1p36.21 G2-M cell cycle arrest 256 
 LTF 3p21.3 Cell cycle regulation 265, 
266 
 CCNA1 13q12.3- q13 An important regulator of the cell cycle required 
for S phase and passage through G2 
267 
 PTPRG 3p14-21 Cell cycle regulator via inhibition of pRB 
phosphorylation through down-regulation of cyclin 
D1 
268 
 TP73 1p36.3 Cell cycle, DNA damage response, apoptosis, 
transcription factor 
255 
Apoptosis 
 DAPK 9p34.1 Positive mediator of gamma-interferon induced 
apoptosis 
243, 
251, 
256, 
257 
 CASP8 2q33-q34 Apoptosis 243, 
255 
 GSTP1 11q13 Apoptosis, metabolism, energy pathways 243, 
251 
 CMTM3 16q21 Induces apoptosis with caspase-3 activation 269 
 CMTM5 14q11.2 Induces apoptosis with activation of caspase 3, 8 
and 9, synergistic effects with TNF-α 
270 
 ZNF382 19q13.12 Key regulator of cell proliferation, differentiation, 
and apoptosis, repress NF-kB and AP-1 signaling 
271 
 TNFRSF11B 8q24 Induces apoptosis, inhibits tumor growth 
specifically in bones 
272 
 PLA2G16 11q12.3 Proapoptotic function through the inhibition of 
PP2A 
267 
Invasion and metastasis 
 CDH1 16q22.1 Calcium-dependent adhesion and cell migration 255, 
257 
 CDH13 16q23.3  Calcium-dependent adhesion and cell migration 273 
 PCDH10 4q28.3 Calcium-dependent adhesion and cell migration 274 
 CDH4 20q13.3 Calcium-dependent adhesion and cell migration 275 
 OPCML 11q25 Cell adhesion, cell-cell recognition 276 
 TFPI2 7q22 Serine protease inhibitor 277 
 MMP19 12q14 Extra cellular matrix 278 
 THBS1 15q15 An adhesive glycoprotein, mediates cell-to-cell and 
cell-to-matrix interactions 
255 
 Cx43 20q11 Gap junction and intercellular communication 279 
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Cancer-related 
process Gene ID 
Chromosomal 
location Function Refs 
 CADM1 11q23 Cell adhesion molecule, mediate cell-cell 
interaction 
280, 
281 
 ADAMTS18 16q23.1 Cell adhesion modulator, inhibits growth factor 
independent cell proliferation 
282, 
283 
 THY1 11q23.3 Regulates cytoskeletal organization, focal adhesion 
and migration by modulating the activity of p190 
RhoGAP and Rho GTPase 
284 
 PCDH8 
 
13q21.1 Cell colony formation and cell migration 285 
 LOX 5q23.2 Inhibits clonogenicity and cell growth 286 
DNA repair 
 MGMT 10q26 Repair alkylated guanine 251 
 MLH1 3p21.3 DNA mismatch repair protein, cell cycle G2-M 
arrest 
255, 
257 
Signal transduction 
 ARF/P14 9p21 Stabilizes p53, interacts with MDM2 243, 
255 
 RASSF1A 3p21.3 Regulate Ras signaling pathway 287, 
288 
 RASFF2A 20p12.1 Regulate Ras signaling pathway 289 
 WIF1 12q14 Antagonist of Wnt signaling 290, 
291 
 DLC-1 8p21.3- 22 GTPase-activating protein specific for RhoA and 
Cdc42 
292, 
293 
 DAB2 5p13 Adaptor molecule involved in multiple receptor-
mediated signaling pathways 
294 
 RASAL1 12q23- q24 Ras GTPase-activating protein, negatively 
regulates RAS signaling 
295 
 UCHL1 4p14 Stabilizes p53 and activates the p14ARF-p53 
signaling pathway 
248 
 SFN 1p36.11 Downstream target of p53, negative regulator of 
G2-M phase checkpoint 
296 
Angiogenesis 
 EDNRB 13q22 Negative regulator of ET/ETAR pathway 297, 
298 
 ADAMTS9 3p14.1 Anti-angiogenesis 299 
 FBLN2 3p25.1 Angiogenesis suppression via concomitant 
downregulation of vascular endothelial growth 
factor and matrix metalloproteinase 2 
300 
Vitamin response 
 RARβ2 3q24 Binds retinoic acid to mediates cellular signaling 
during embryonic morphogenesis, cell growth and 
differentiation 
251, 
301, 
302 
 RARRES1 3q25 Retinoic acid target gene 267, 
303, 
304 
 RBP1 3q23 Draws retinol from blood stream into cells, 
solubilizes retinol and retinal, protects cells from 
membranolytic retinoid action 
301 
 RBP7 1p36.22 Draws retinol from blood stream into cells, 
solubilizes retinol and retinal, protects cells from 
membranolytic retinoid action 
301 
Tissue development and differentiation 
 Myocd 17p11.2 Transcription factor, involved in smooth muscle 
cell differentiation 
305 
 SCGB3A1 5q35 Involved in epithelial cell differentiation, cell-cycle 
reentry regulator, suppresses tumor cell migration 
and invasion, induces apoptosis 
306 
Others 
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Cancer-related 
process Gene ID 
Chromosomal 
location Function Refs 
 NR4A3 1p34.3 Interaction partner of the mitochondrial ATP 
synthase subunit OSCP/ATP5O protein, a stress-
responsive gene 
307 
 LARS2 3p21.3 Essential roles in group I intron RNA splicing and 
protein synthesis within the mitochondria, 
indirectly required for mitochondrial genome 
maintenance 
308 
 CRYAB 11q23.1 An important nuclear role in maintaining genomic 
integrity 
309 
 CYB5R2 11p15.4 Carcinogen metabolizing enzyme 310, 
311 
CDKN2B: Cyclin-dependent kinase inhibitor 2B; ADAMTS18: ADAM metallopeptidase with 
thrombospondin type 1 motif, 18; ADAMTS9: A disintegrin-like and metallopeptidase with 
thrombospondin type 1 motif 9; ARF: Alternate open reading frame; BRD7: Bromodomain containing 7; 
CADM1: Cell adhesion molecule 1; CASP8: Caspase 8; CCNA1: Cyclin A1; CDH1: Cadherin 1; 
CDH13: Cadherin 13; CDH4: Cadherin 4; CHFR: Checkpoint with forkhead and ring finger domains; 
CMTM3: CKLF like MARVEL transmembrane domain-containing member 3; CMTM5: CKLF like 
MARVEL transmembrane domain-containing member 5; CRYAB: Crystallin, alpha B; Cx43: Connexin 
43; CYB5R2: Cytochtome b5 reductase 2; DAB2: Disabled homolog 2; DAPK: Death-associated protein 
kinase; DLC-1: Deleted in liver cancer-1; DLEC1: Deleted in lung and esophageal cancer1; EDNRB: 
Endothelin receptor type B; FBLN2: Fibulin 2; FHIT: Fragile histidine triad gene; GADD45G: Growth 
arrest and DNA-damageinducible, gamma; GSTP1: Glutathione Stransferase pi 1; LARS2: Leucyl-tRNA 
synthetase 2; LOX: Lysyl oxidase; LTF: Lactoferrin; MGMT: O-6- methyoguanine- DNA 
methyltransferase; MIPOL1: Mirror-image polydactyly1; MLH1: MutL homolog 1; MMP19: Matrix 
metalloproteinase- 19; Myocd: Myocardin; NR4A3: Nuclear receptor subfamily 4, group A, member 3; 
OPCML: Opioid binding protein/cell adhesion molecule like; PCDH10: Protocadherin 10; PCDH8: 
Protacadherin 8; PLA2G16: Phospholipase A2, group XVI; PRDM2: PR domain containing 2, with ZNF 
domain; PTPRG: Receptor-type tyrosine-protein phosphatase gamma; RARRES1: Retinoic acid receptor 
responder (tazarotene induced) 1; RARβ2: Retinoic acid receptor beta 2; RASAL1: RAS protein activator 
like 1; RASFF2A: Ras association domain family member 2A; RASSF1A: Ras association domain family 
member 1A; RBP1: Retinol binding protein 1; RBP7: Retinol binding protein 7; SCGB3A1: 
Secretoglobin, family 3A, member 1; SFN: Stratifin; TFPI2: Tissue factor pathway inhibitor- 2; THBS1: 
Thrombospondin 1; THY1: Thy-1 cell surface antigen; TNFRSF11B: Tumor necrosis factor receptor 
superfamily, member 11b; TP73: Tumor protein p73; UCHL1: Ubiquitin carboxyl-terminal esterase L1; 
WIF1: Wnt inhibitory factor-1; ZMYND10: Zinc finger, MYND-type containing 10; ZNF382: Zinc finger 
protein 382. 
 
1.3.5.1 Epigenetic regulation of EBV gene expression 
In NPC, DNA methylation associated gene silencing is not limited to the inactivation of 
cellular TSGs. It has been shown that DNA methylation also modifies the Wp and Cp 
promoters in the EBV genome that leads to the silencing of several EBV genes (nuclear 
proteins EBNA2, 3A, 3B and 3C). This also plays an important role in the 
establishment of EBV latency type in NPC.312, 313 The expression of EBV LMP1 
oncogene in NPC is associated with its promoter methylation status.314 Epigenetic 
regulation of cellular and EBV genes plays a significant role in NPC tumorigenesis, 
although not yet fully understood. 
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1.3.5.2 Role of EBV in DNA epigenetic regulation of genes in NPC 
EBV-associated NPC originates from the monoclonal proliferation of EBV-infected 
epithelial cells.247, 315. EBV infection is reported to induce genome-wide increase in 
methylation in EBV-associated NPC.254, 316 In comparison with EBV-negative NPC, 
unique epigenetic profiles with much higher frequencies of TSG promoter 
hypermethylation has been shown in EBV-positive NPC.243 EBV may act as an 
epigenetic driver for the NPC tumorigenesis,243, 247, 317 EBV oncoprotein LMP1 has 
been shown to drive DNA hypermethylation by activating cellular DNA 
methyltransferases through c-jun NH2- terminal kinase signaling and subsequently 
induce hypermethylation of several cellular TSGs.318, 319 LMP1 has also been suggested 
to play a role in hypermethylation of several EBV and cellular TSGs by upregulating 
DNMT1 and polycomb group (PcG) protein Bmi-I.320 The histone modifications 
mediated by PcG also has a role in the hypermethylation of certain TSGs.321.  
1.3.5.3 Detection of NPC using hypermethylated TSGs 
Most studies on detection of NPC based on epigenetic marks have employed analysis 
of promoter methylation of TSG panels.322 In an earlier work,323 DNA samples either 
from NPC paraffin fixed samples or nasopharyngeal brushings were analyzed for ten 
TSGs by using MSP method. Of these CADM1, CDH13, DAPK1, DLC1 were 
frequently methylated in individuals with elevated EBV IgA and viral load. A 
combination of CHFR, p16, RASSF1A, RIZ1 and WIF1 as methylation markers was 
reported to detect 98% of the NPC samples.323 Other studies have also reported 
differential methylation of genes such as CDH1,251, 252, 256, 324, 325 p16,251, 256, 306, 324 
RARβ2,251, 253, 303 RASSF1A251, 253, 256, 306, 324 to be useful biomarker for the detection of 
NPC (Table 2). 
1.4 Introduction to lung cancer 
Lung cancer is the leading cause of cancer-related deaths worldwide. Its incidence 
and mortality is increasing steadily.326 It accounts for nearly 13% (1.6 million cases) 
of all cancer cases and 18% (1.4 million) cancer deaths each year on a global scale.327 
In China, lung cancer is the most common type of cancer detected in the male 
population (350  000 cases, 21.7% of all cancers) and is the second most common type 
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of cancer in the female population (170  000 cases, 14.3%) after breast.328 It has 
shown a dramatic increase of 4.7 times over the past three decades in China.329 
Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC).330 NSCLC accounts for about 80% of the global lung cancer cases.331 
Histologically, NSCLC is classified into adenocarcinoma, squamous cell carcinoma, 
and large cell carcinoma.330 NSCLC shows a slower growth and spread pattern as 
compared with SCLC.332 The higher mortality rate of NSCLC patients can be 
attributed to its late diagnosis at an advanced stage of the disease.333 The reasons for 
late diagnosis are the late appearance of symptoms.332 
1.4.1 Epigenetic aspect of non-small cell lung cancer 
In lung cancer, epigenetic alterations are more frequent than genetic mutations.334 
Dysfunctional epigenetic mechanisms, such as DNA methylation, histone 
modifications and ncRNA regulation are common events in lung cancer which can lead 
to development of lung cancer by activating oncogenes and silencing TSGs.335, 336  This 
makes epigenetic alterations potentially interesting biomarkers for early diagnosis in 
cancer.337-339 
DNMTs are upregulated in NSCLC.340-342 Promoter hypermethylation of genes 
involved in key cellular functions such as cell cycle regulation, proliferation, apoptosis, 
cellular adhesion, motility, DNA repair and genome stability is frequently reported.343 
The aberrant methylation of several genes involved in important cellular processes 
such as DAPK, RASSF1A, p16, MGMT, DAPK, RASSF1A, PAX5β, GATA5 and 
CXCL14 has been associated with lung cancer tumorigenesis.344-348 The aberrant 
promoter DNA methylation of p16 and/or MGMT genes was detectable in sputum of 
all the SCC subtype of NSCLC patients up to three years before their clinical 
diagnosis.349 Short stature homeobox 2 (SHOX2) hypermethylation has also been 
suggested to be a potential marker for diagnosis of lung cancer. 350 
Genome-wide hypomethylation has also been reported during NSCLC development.351 
It has been associated with genomic instability352 activation of the proto-oncogenes353, 
354 and loss of imprinting.355 In lung cancer, genomic hypomethylation has been 
reported at nuclear elements, long terminal repeat elements, segmental duplicates, and 
sub-telomeric regions.356  
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Histone modifications have been reported in lung cancer where HDACs are 
overexpressed.42, 357, 358 Hyperacetylation at H4K5/H4K8, hypoacetylation at 
H4K12/H4K16 and loss of trimethylation at H4K20 are frequent in lung cancer.359  
Expression of miRNAs is also deregulated in lung cancer.360, 361 For example, as 
compared to normal cells, miR-196a and miR-200b are reported to be 23 times and 37 
times overexpressed in lung cancer cells respectively.360 lncRNAs such as metastasis-
associated lung adenocarcinoma transcript 1 (MALAT-1) and HOTAIR have also been 
observed to be upregulated in NSCLC.362-366 MALAT-1 is involved in silencing of 
genes that regulate cell migration, invasion, and metastasis.367-369 HOTAIR is involved 
in the regulation of HOXD expression.370 
Cross-talk between different epigenetic mechanisms has also been observed in lung 
cancer. For example, hypermethylation of miR-124a,371 miR-34b/c,190, 191 miR-9-
3,372 and miR-193a372 has been reported in lung cancer. Moreover, miR-29 targets the 
transcripts of DNMT3a and DNMT3b and restores their normal DNA methylation 
patterns.373  
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2 AIMS OF THIS STUDY 
1. To evaluate MMSP assays for simultaneous detection of methylations status 
of multiple genes. Evaluate its feasibility for identifying NPC using 
nasopharyngeal swabs as source of DNA (Paper I). 
2. Update the MMSP assay with a panel of markers suitable for NPC detection 
in different NPC endemic areas and to evaluate the feasibility of MMSP for 
detection of aberrant DNA promoter hypermethylation in samples from 
different geographical regions (Paper II).  
3. To search for putative TSGs in chromosome 3 in NPC by Not I arrays and 
analyze if such candidate genes are regulated by promoter methylation (Paper 
III).  
4. To select specific and sensitive markers genes, which are hypermethylated 
and downregulated, for development of an MMSP assay for lung cancer 
(NSCLC). Evaluate the feasibility of MMSP for simultaneous detection of 
several aberrantly methylated genes in samples from NSCLC (Paper IV).  
5. To try several different approaches for identification of candidate marker 
genes for the MMSP assays: high throughput expression and methylation 
microarrays, NotI microarray and literature searches (all papers). 
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3 RESULTS AND DISCUSSION 
3.1 Paper I 
Development of a non-invasive method, multiplex methylation specific PCR 
(MMSP), aiming for early detection of nasopharyngeal carcinoma 
DNAs from seven NPC cell lines including a xenograft were used in this study to 
validate the reproducibility of the MMSP assay. C15 is an African-origin NPC 
xenograft which is EBV-positive and expresses LMP1. C666-1 is an EBV-positive 
and LMP1 non-expressing NPC cell line. The other five NPC-derived cell lines used 
in this study i.e. CNE1, CNE2, HONE1, SUNE1 and HK1, are all EBV negative. The 
EBV-gene EBNA1 was used as a marker for the presence of EBV in the MMSP 
assay. It can be detected in the C666-1 cell line and the C15 xenograft. 
Unmethylated-LMP1 can only be detected in the LMP1 expressing xenograft, C15. 
None of the other cell lines showed signals for EBNA1 or LMP1. All cell lines and 
the xenograft showed hypermethylation of at least one of the two TSGs, included in 
the MMSP assay, i.e. RASSF1A and DAPK 
DNAs from 49 NPC biopsies and their corresponding nasopharynx swabs were 
included in this study to examine the reliability of nasopharyngeal swabs as the 
source of DNA for the MMSP assay. DNA from nasopharyngeal biopsies and 
corresponding swabs from 20 non-cancerous volunteers were also included as 
controls. All DNAs from NPC and control swab samples showed detectable signals 
for β-Actin gene in our MMSP analysis, indicating enough DNA yield as well as 
efficient bisulfite conversion of DNA. EBV-encoded EBNA1 was detected in 100% 
(49/49) of the NPC tumors and 98% (48 of 49) of their paired swab samples. All 
controls were negative for EBNA1. Unmethylated LMP1 (U-LMP1) was detected in 
63% (31/49) of NPC tumors and in 55% (27/49) of their corresponding swab 
samples, suggesting expression of LMP1 in these samples. Our U-LMP1 result in 
NPC samples is consistent with the reported expression level of LMP1 in NPC. The 
sensitivity (Sn) for detection of hypermethylated of RASSF1A and DAPK were 80% 
(39/49) and 67% (33/49) in the biopsy samples, respectively, while 55% (27/49) and 
57% (29/49) respectively in the DNA from their matched swabs. 
Among DNA samples from NPC swabs 18% (9/49) were positive for all four MMSP 
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markers, 35% for three, 31% for two, and 14% for one marker only. Around 43% of 
the nasopharyngeal swabs showed a pattern in the MMSP assay which matched 
perfectly with the corresponding biopsies. If we include the presence of EBNA1 plus 
at least any one of the other three markers as a diagnostic criterion for NPC, we 
reached a Sn of 98% in the swab samples. No EBV or methylated markers were 
found in DNAs from swabs of the controls, suggesting 100% specificity (Sp). This 
result supports the idea to develop MMSP to a screening tool in high-risk 
populations. Since patterns and timing of methylation status of specific genes are also 
associated with defined biological behaviors,374 the MMSP method carries the 
potential to predict individual tumor behavior, given that the appropriate genes are 
included in the assay. EBV load and methylation levels of some specific genes have 
been shown to detect disease relapse after treatment.375, 376 
Considering the flexibility of the MMSP panel, allowing replacement of tumor-
specific markers it will be possible to extend the usage of MMSP assay for diagnosis 
of other cancers using body fluids, such as urine to detect prostate cancer or bladder 
cancer, cervical cancer by cervical swab and lung cancer by sputum or saliva etc. 
(Paper IV). 
3.2 Paper II 
Detection of nasopharyngeal carcinoma (NPC) from different geographic 
regions using multiplex methylation specific PCR (MMSP) biomarker assay 
We set out to evaluate and explore combinations of several genes and to try to 
improve our MMSP assay for NPC (Paper I), so that it can be used on samples from 
different geographical locations. The DNAs from 44 NPC and 18 normal biopsy 
samples from Morocco were screened using single gene MSP for 12 markers, 
including those used in paper I, and in addition eight new markers i.e. ITGA9, p16, 
WNT7A, CHFR, CYB5R2, WIF1, RIZ1 and FSTL1. Of the Moroccan NPC samples, 
36 (82%) were positive while eight samples (18%) were negative for EBNA1. This 
differs from the pattern in Chinese NPC (Paper I). Among marker genes used in 
Paper I, RASSF1A was positive in 29/44 and thus was the most sensitive marker 
(66%) after EBNA1. DAPK showed the lowest sensitivity 11/44 (25%) and 
specificity 13/18 (72%) in Moroccan NPC. These results demonstrated the need of 
replacement of DAPK with a more informative marker with higher Sn and Sp. Of the 
  30 
eight additional genes that were tested in the DNA samples from Moroccan NPC and 
controls ITGA9: 22/44 (50%) (Paper III) and p16: 20/44 (45%) were the two marker 
genes with highest Sn showing 100% Sp. On the basis of MSP results a modified 
MMSP assay was developed which contained EBNA1, LMP1, RASSF1A as before 
while DAPK was replaced with ITGA9 and p16. The house keeping reference gene 
β-ACTIN was also replaced with GAPDH to make the developed MMSP assay better 
suitable for both biopsy and serum samples.  
This modified MMSP was used to screen 64 NPC biopsies from three different 
geographical regions (Morocco 44, Italy 15 and China 5) and 20 non-cancerous 
nasopharyngeal biopsies from two different geographical regions (Morocco 18 and 
China 2). At least any one modified MMSP marker could be detected in 91% NPC 
biopsy samples with 90% specificity. We could also identify three out of eight EBV 
negative samples with at least one cellular marker. In 16 NPC serum samples from 
two different geographical regions (Italy 11 and China 5) we could detect at least any 
one MMSP marker in 88% samples but the specificity was as low as 50%.  
We did not observe any marked differences in the methylation patterns among 
samples from different geographical locations. This MMSP panel seems to work on 
samples from different geographical locations. 
3.3 Paper III 
Integrin α9 gene promoter is hypermethylated and downregulated in 
nasopharyngeal carcinoma 
Changes in chromosome 3, which harbors several TSGs, are common in many 
tumors.377 NotI microarray (NMA) was performed to screen for potentially 
methylated genes in chromosome 3 in NPC using genomic DNA from three NPC 
tumor biopsies, two control nasopharyngeal epithelial tissues, three NPC cell lines 
(CNE1, TWO3 and C666-1) and one control nasopharyngeal epithelium derived cell 
line NP69. Ten genes (ALDH1L1, BCL6, EPHB3, FGD5, FGF12, ITGA9, 
NUDT16P, RBSP3, WNT7A and ZIC4) were identified with the NMA showing 
reduced signal in NPC samples as compared to control samples suggesting 
methylation or deletion of these genes in NPC. Correlation between hypermethylation 
and downregulation of these genes was investigated by performing MSP and Q-PCR. 
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After further analysis only two genes i.e. ITGA9 and WNT7A qualified for further 
validation for their downregulation by promoter hypermethylation. This shows the 
limitations for such screening using NMA. 
Downregulation of ITGA9 and WNT7A was observed in NPC samples as compared 
to normal samples using immunostaining performed on three cases of NPC tumor 
cells and adjacent normal nasopharyngeal epithelium. 
Treating CNE1 and TWO3 with demethylating agent 5-aza-2′-deoxycytidine (5-aza-
C) restored ITGA9 and WNT7A expression which supported a hypermethylation of 
the promoters of ITGA9 and WNT7A. This was further confirmed by performing 
MSP and Q-PCR after the 5-aza-C treatment. 
The methylation status of the CpG rich region in the ITGA9 gene promoter was 
investigated by bisulfite sequencing in nine NPC biopsies and six control 
nasopharyngeal epithelia biopsy. This region containing 11 CpG sites and was 
partially methylated in all NPC samples, whereas only a few CpG sites were partially 
methylated in the control samples. Similarly methylation status of the CpG rich 
region in the WNT7A gene promoter was investigated by bisulfite sequencing in four 
NPC biopsies and three control nasopharyngeal epithelia biopsies. This region 
contained 84 CpG sites. The WNT7A promoter was partially methylated in the four 
NPC samples. There was virtually no methylation in the two control samples while 
one control sample showed some methylation at several CpG sites. Taken together 
these results suggested that ITGA9 would be a better candidate as a hypermethylated 
marker gene in NPC than WNT7A.  
The hypermethylated status of the ITGA9 gene promoter was quantitatively validated 
using pyrosequencing of bisulfite converted DNA. Two pyrosequencing assays 
targeted seven CpGs that were located in the same region that had been before 
sequenced by cloning of bisulfite converted DNAs. Five biopsies and two control 
nasopharyngeal epithelia biopsies were sequenced with this method. The majority of 
the CpGs in ITGA9 gene promoter were partially methylated in all the NPC samples, 
while they were unmethylated in the control samples.  
ITGA9 expression in four control epithelial tissues and three NPC samples was 
analyzed by using  Q-PCR. The average expression level of ITGA9 was 4.0±2.6 in 
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NPC vs. 19.9±10.2 in the controls. ITGA9 expression was downregulated in NPC 
tumor samples as compared to control nasopharyngeal epithelium. 
Methylation specific PCR was used to screen DNA from 36 EBV positive NPC biopsy 
samples and 18 non-cancerous control samples from Morocco. ITGA9 methylation was 
detected by MSP in 56% of NPC DNA samples with 100% specificity. WNT7A 
methylation was detected by MSP in 69% of the samples but was less specific (83%). 
Although WNT7A shows higher sensitivity the low level of specificity makes it less 
attractive to include in screening methods like MMSP. However ITGA9 also is not 
optimal with a relatively low sensitivity. Nevertheless we employed ITGA9 as one 
marker in the MMSP assay for NPC in paper II. 
Our results suggest that ITGA9 might be a TSG in NPC and promoter 
hypermethylation one mechanism for downregulation. Aberrant methylation and/or 
downregulation of ITGA9 has been reported in multiple human cancers.378-382 We 
found that ITGA9 is methylated and downregulated in Chinese NPC patients.  
Integrin α9 forms a heterodimer with β1 chain to form a single integrin, α9β1.383 This 
receptor plays an important role in different signal transduction pathways controlling 
cellular proliferation and differentiation. Integrin α9β1 mediates cell migration in 
glioblastoma.384 As ITGA9 protein executes significant functions related to tumor cell 
biology, in depth functional studies are relevant to understand its functional role in 
the development of NPC.  
Our results suggest that ITGA9 aberrant epigenetic deregulation of the ITGA9 gene 
could be useful for future diagnostic approaches in NPC. We explored the possibility 
of using hypermethylation of ITGA9 as a diagnostic mark for NPC and for this 
purpose we have included ITGA9 into our assay for early detection of 
nasopharyngeal carcinoma (Paper II). 
3.4 Paper IV 
Development of a multiplex methylation specific PCR suitable for (early) detection 
of non-small cell lung cancer 
Methylation and expression microarrays were performed on three NSCLC and matched 
distant non-cancerous tissue pairs to identify hypermethylated and downregulated 
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genes. From these array results 22 genes were identified. The most informative 11 of 
the 22 markers with 27 additional methylation regulated TSGs 38 (11+27) identified in 
the literature were pre-screened on a small group of DNA samples from lung cancer 
and matched control tissues by MSP. The six markers with the highest Sn and Sp 
identified from this screening were HOXA9, TBX5, PITX2, CALCA, RASSF1A and 
DLEC1. These six markers were employed in an MMSP assay testing 70 NSC lung 
cancer with matched controls and 24 additional normal lung tissue samples from 
patients with benign pulmonary lesion.  
Among these six genes, HOXA9 showed the highest Sn i.e. 87% (61/70) whereas 
DLEC1 was lowest with a Sn of 37%. RASSF1A and DLEC1 provided the highest Sp 
as 99% (69/70) whereas the TBX5 showed the lowest Sp 86%. All DNAs from 24 
normal lung tissue samples from patients with benign pulmonary lesion were negative 
using these six methylation markers. Methylation of RASSF1A was significantly 
different between treated and untreated patients. HOXA9 showed a significant 
difference between smokers and non-smokers.  
Among the 70 NSCLC tissue samples, 61 samples were methylated in at least two up 
to six markers in different combinatorial patterns. The Sn and Sp for at least any two 
markers were 87% and 94% respectively. An increase in the number of minimal 
markers increased the specificity but the sensitivity reduced e.g. the Sn and Sp for at 
least any three markers were 76% and 97% respectively. All six markers were 
methylated in 21% samples with 100% specificity. Thus, the Sn and Sp revealed by at 
least any two of the marker genes reached levels which are fit for NSCLC detection. 
More importantly with this criterion we could detect 86% (24/28) of the stage I and II 
samples with a Sp of 100% (28/28). MMSP did not detect methylation in any of the 
markers in any of the 24 normal lung tissue samples from patients with benign 
pulmonary lesion whereas its detection rate for any one marker for cancer sample was 
99% (69/70). Although this is a satisfactory outcome of the evaluation of this MMSP, 
one might still consider to combine it with detection of “diagnostic” mutations.	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4 METHODS 
For details of protocols see the individual papers. This chapter contains a brief 
discussion of methods used in this thesis in the context of available other methods. 
4.1 Extraction of DNA  
Several methods were employed but conventional phenol-chloroform method provides 
high yields of pure DNA, and performs better than commercial kits particularly when 
working with small biopsies (which is usually the case for NPC). 
4.2 Bisulfite treatment of DNA 
Techniques for analyzing the methylation status of DNA may provide information 
from genome-wide methylation level to methylation of single residues in specific 
genes (Figure 13). Each one of such techniques has its own limitations that may affect 
the interpretation of data. For example, high performance liquid chromatographic 
(HPLC) or array based methods can be used to analyze DNA methylation at global or 
genomic levels while other techniques, such as pyrosequencing and MSP, can be used 
to analyze methylation of a specific small set of CpGs.385 Currently several high-
throughput methods of genome-wide methylation analysis have been developed and 
are widely used. They require some validation by gene- or locus-specific methods. 
 
Figure 13. Classification of techniques for DNA methylation studies. Cited from Shen and Waterland 
RA 2007.385 
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DNA methylation analysis methods can be broadly grouped on the basis of different 
techniques used for pretreatment of DNA such as affinity enrichment of methylated 
DNA, chemical modification with sodium bisulfite, and digestion with methylation-
sensitive restriction enzymes.386 In techniques based on affinity enrichment of 
methylated DNA, such as methyl-DNA immunoprecipitation (MeDIP) and methyl 
CpG binding protein capture (MBDCap), DNA is enriched with anti-5mC antibodies 
or MBD proteins for DNA methylation analysis.71, 387 In methods like HPLC, 
enzymatic hydrolysis of the DNA is done before analysis.388 In other procedures, such 
as, restriction landmark genomic scanning (RLGS), DNA is pretreated with 
enzymatic digestion.389 But the majority of techniques such as bisulfite-based 
genomic sequencing, MSP, bisulfite pyrosequencing, Illumina® and combined 
bisulfite restriction analysis (COBRA), depend on the pre-treatment of genomic DNA 
with sodium bisulfite, originally described in 1970.390  
Bisulfite modification of DNA converts unmethylated cytosine residues to uracil with 
no effect on methylated cytosines. It is the golden standard for detection of the 
methylation status of CpGs in a sequence-specific context. Table 3 enlists some of the 
techniques in which bisulfite treated DNA is used.  
Table 3. Some techniques for DNA methylation analysis based on bisulfite converted 
DNA. 
Technique Application Ref. 
Bisulfite genomic sequencing Qualitative analysis 391-393 
MSP Qualitative analysis 394, 395 
MS-HRM Qualitative analysis 396-398 
Ms-SnuPE Quantitative analysis 399 
COBRA Quantitative analysis 400 
Methylight or Q-MSP Quantitative analysis 401-405 
MS-DGGE Complex informational analysis 406 
MS-SSCA Complex informational analysis 407 
MS-DHPLC Complex informational analysis 408 
Illumina Marker discovery 409-411 
MSO Marker discovery 412 
MSP: methylation specific PCR; MS-HRM: Methylation-sensitive high resolution melting; Ms-
SnuPE: methylation-sensitive single nucleotide primer extension; COBRA: combined bisulfite 
restriction analysis; Q-MSP: quantitative methylation specific PCR; MS-DGGE: methylation-
specific denaturing gradient gel electrophoresis; MS-SSCA: methylation- specific single-strand 
conformation analysis; MS-DHPLC: methylation-specific denaturing high-performance liquid 
chromatography; MSO: methylation-specific microarray. 
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Prior denaturation of the DNA before bisulfite treatment is a critical step as bisulfite 
efficiently converts cytosine bases only in single DNA strands. The differential 
deamination of cytosine by bisulfite treatment involves sequential sulfonation, 
hydrolytic deamination and alkaline desulfonation. This results in two DNA strands 
that are no longer complementary to each other because of the C – U conversion of 
unmethylated cytosines induced in both individual DNA strands by bisulfite. 
Incomplete C - U conversion is the most important limitation of the bisulfite approach 
that could lead to false positive results. In addition there is a risk of DNA 
degradation. Some newly developed techniques, such as a solid-state nanopore-based 
methylation sensitive assay, do not require bisulfite conversion. This assay also does 
not require fluorescent labeling and PCR. Such methods could therefore prove very 
useful in studying the role of DNA methylation in human disease.413 
4.3 Methylation specific PCR 
Methylation specific PCR (MSP) is widely used for studying the methylation status 
of CpG dense regions that are frequently found in the promoters of many TSGs. 
Cytosines in CpG rich regions are usually unmethylated in normal tissues, but 
become hypermethylated in cancer-associated genes. The differences between 
methylated and unmethylated alleles after bisulfite modification of cytosine residues 
make the basis of MSP. The primers for MSP are designed according to these 
differences to distinguish between the differential methylation statuses. This is why 
MSP primer designing is a critical step for a successful MSP assay. The MSP primers 
should be designed with the following considerations: 
i. the annealing temperatures of both the primers must be similar ranging 
between 55 to 65°C; 
ii. the size of the PCR product should be between 80 and 250 bp; 
iii. each primer should contain at least two CpG dinucleotides; 
iv. both the primers should have at least one CpG at its 3′-end; 
v. each primer should contain some non-CpG cytosines to avoid false positives 
results because of amplification of unmethylated but still unmodified DNA.  
MSP is a simple and cost efficient technique. As the bisulfite treatment also causes 
some degradation of the DNA the MSP reaction conditions should be optimized. As 
the MSP is a very sensitive method and can detect one methylated DNA copy in 
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thousand unmethylated DNA copies which makes the optimization of the PCR assay 
such as number of magnification cycles very important for the reliability of the 
results. A weakness of the system is the subjective nature of the results which, in the 
future needs to be addressed by developing it into a quantitative method for the 
analysis of multiple markers such as quantitative digital MSP.  
4.4 Multiplex methylation specific PCR 
Multiplex methylation specific PCR (MMSP) is a useful technique for studying the 
methylation status of multiple biomarkers in a single reaction. For MMSP less DNA 
is needed which makes it more material-economic than simple MSP. Principally, 
MMSP is based on the same principle as MSP, except that the analysis is run in a 
single reaction tube and all included genes are amplified proportionally according to 
optimization by MSP. The increased number of primers needed (two for each gene) 
makes the primer design more tedious. This method is particularly useful in case of 
limited amount of sample, e.g. when starting with small biopsies.  
4.5 Cell lines or tumor tissues 
We employed cell lines from NPC, Burkitt’s lymphoma and NSCLC. Cell lines are 
excellent tools for mechanistic studies as well as for generating hypothesis about 
epigenetic regulation of specific genes. However their epigenetic profile may be 
deformed compared to the tissue/tumor of origin due to explantation and the specific 
conditions of in vitro growth. There are also concerns regarding the identity and correct 
tissue origin of cell lines.  
To map a more tumor/tissue correct epigenetic profile it is necessary to use ex vivo 
biopsy material. However, tumor biopsies contain a large proportion of non-tumor 
infiltrating and stromal cells, which may constitute half or more of the tumor tissue. 
NPC is, for example, well known to be heavily invaded by CD4+ T-cells. Such cell 
dilute signals specific for the tumor cells. Tumors are also known to show great intra- 
and inter-tumoral heterogeneity, which might be evaluated by micro-dissection and the 
use of large cohorts of patient biopsies. 
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4.6 Treatment of cells with 5-aza-2’-deoxycytidine 
5-aza-C is an analogue of the cytosine nucleotide. When incorporated into DNA, it 
inhibits DNMTs.414 Thus, in vitro treatment of cells with 5-aza-C leads to 
demethylation of the cytosines as de-novo synthesized DNA cannot be methylated. 
This may result in activation of silent genes, such as hypermethylated TSGs in cancer 
cells. It is important to optimize time and dosage for 5-aza-C treatment individually 
for each cell line.  
4.7 Bisulfite sequencing of cloned PCR products 
Sequencing of bisulfite converted DNA is a means of identifying methylated cytosine 
residues with a specific sequence/gene. Bisulfite converted DNA can be directly 
sequenced but unlike the sequencing of clones, which was done in our work, the 
direct method of bisulfite sequencing produces average methylation values for 
populations of DNA molecules. 
The challenging step for successful bisulfite sequencing is the primer design. 
MethPrimer is a good online tool for designing primers for bisulfite sequencing 
(http://www.urogene.org/methprimer/index1.html). The software identifies CGIs the 
DNA sequence of study. Primers around the CGIs are then suggested by the software 
(or in other regions specified by the user). The NCBI database “Gene” 
(http://www.ncbi.nlm.nih.gov/gene) was used to find the molecular location of our 
target genes. The UCSC genome browser (http://genome.ucsc.edu) was used to get 
the DNA sequence. RefSeq Genes filter was used to mark the exons.  
4.8 Pyrosequencing of bisulfite converted DNA 
The pyrosequencing technology is based on sequencing-by-synthesis. It relies on the 
luminometric detection of inorganic pyrophosphates (PPi) which are released by the 
incorporation of nucleotides catalyzed by primer-directed DNA polymerase. 
Unincorporated nucleotides are subsequently degraded by nucleotide-degrading 
enzyme - Apyrase. Addition of dNTPs is performed sequentially according to the 
template sequence. DNA stretches up to only one hundred bases can be sequenced with 
this method, which is a limitation. It provides the advantages of precision, flexibility, 
parallel processing and can also be easily automated. The technique does not need 
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labeled primers, labeled nucleotides nor gel electrophoresis. Compared to conventional 
sequencing based on plasmid clones with inserted DNA fragments, pyrosequencing is 
fast, simple to use and delivers sequence data in real-time with high accuracy and 
quantity. This protocol has been reported to detect DNA methylation levels as low as 
5%.415  
4.9 Immunostaining 
Immunostaining is performed for the detection of protein expression in tissue sections 
with specific antibodies. This can provide information about the location where protein 
is being expressed and also the intensity of the positive signal. The immunostaining 
results were analyzed, evaluated and scored by senior pathologists with no knowledge 
of the clinicopathological outcome of the patients. The most critical aspect of 
immunostaining is the quality of the antibodies used: their sensitivity and specificity. 
4.10 NotI microarray 
This method can be used for genome-wide search for methylated or deleted genes. The 
principle of the method is that NotI restriction enzyme cuts only unmethylated CpG 
pairs located within the NotI recognition site (5’-GCGGCCGC-3’).416 NotI digested 
fragments make up only a small fraction (0.1-0.05%) of the human genome and are 
almost exclusively positioned in CGIs. The NMA we used, covers 188 potential TSGs 
in chromosome 3, the region we focused on, to compare the normal and tumor cells at 
the chromosomal level. NotI microarray makes it possible to screen for overall patterns 
of methylation/deletion patterns in normal and cancer cells.417 
4.11 Methylation microarray 
Illumina infinium® methylation assay (Illumina Inc. USA) is the most widely used 
array-based methylation profiling platform. By applying the principle hybridization 
between two complementary strands of nucleic acids, Illumina Infinium 
HumanMethylation450 BeadChip can detect the DNA methylation status of 99% of 
genes and 96% of CGI regions throughout the genome in a single experiment.418 For an 
individual CpG site, a pair of bead-bound probes is used to detect the presence of T 
(unmethylated state) or C (methylated state). Beta values range from 0 (completely 
unmethylated) to 1 (fully methylated) and provide a quantitative readout of relative 
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DNA methylation for each CpG site, which relates to the percentage of methylation for 
a given site. 
4.12 Expression microarray 
Various manufactures produce genome-wide gene expression microarray platforms. 
Expression arrays from Affymetrix (Affymetrix Inc. USA) and Agilent (Agilent 
technologies USA) make use of short oligonucleotides to investigate gene expression 
levels. Illumina ((Illumina Inc. USA) uses BeadArray technology based on 3-micron 
silica beads. Each bead contains millions of copies of a specific oligonucleotide that 
act as capture sequences. Developments of the techniques have made it possible to 
incorporate more probes in a single array allowing higher accuracy in the estimate of 
gene expression levels. For example, the number of probes per array in Affymetrix 
GeneChip platform has increased over 100-fold, from the early versions (45,000 
probes) to the later (5,500,000 probes). 
4.13 Statistical analysis 
The correlation between gene expression and clinicopathological parameters were 
assessed using Chi-Square test. Differences were considered as significant when p < 
0.05. Sensitivity was calculated as the percentage of the number of positive cases in the 
patients divided by total number of cases tested. Specificity was calculated as the 
percentage of the total number of tested controls minus number of positive cases in 
controls divided by total number of tested controls. 
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5 CONCLUDING REMARKS 
In this work, we have tried to identify and evaluate the possibility to use aberrant 
DNA methylation in cancer (NPC and NSCLC) as a marker for detection of the 
cancer. A number of methods have been used to identify marker genes possible to use 
in an MMSP assay. These included methylome and expression arrays, Not I 
microarray, methylation sensitive PCR and literature searches. For some novel 
candidates in vitro cell assays were used as complement to study impact of control by 
methylation. The MMSP assay was mostly applied on tumor material, but also on 
DNA from nasopharyngeal swabs and serum. The main conclusions were: 
1. We developed MMSP assays for NPC and NSCLC. This as an assay which 
allows simultaneous detection of methylated DNA sequences, in our case 
derived primarily from aberrantly methylated promoter regions. The 
sensitivity and specificity of MMSP in detecting 49 NPC swabs was 98% and 
100% respectively. It is only semi-quantitative, but could probably be 
developed to be quantitative utilizing multiple color based Q-PCR. Our assay 
could simultaneously detect EBV and methylation status of multiple viral and 
cellular genes using DNA from nasopharyngeal swabs.	  2. This MMSP assay was modified in an attempt to optimize it for NPC-
detection in different high/medium-risk areas. With this modification it 
worked equally well in three different geographical countries, although some 
of the materials were small due to shortage of biopsy material. We could 
detect NPC markers in some of the EBNA1 negative cases. A first effort was 
made to apply the MMSP assay on a small set of NPC serum samples, but the 
result was disappointing. NP swabs seemed much more useful. To use blood 
as a source sensitivity and specificity has to be increased. One way may be to 
use whole blood or plasma as a source, or even start by isolation of circulating 
tumor cells. Further development of the approach is definitely needed before 
it can be tested in population-based screening for early detection of cancer.	  3. We discovered two additional genes, ITGA9 and WNT7A, where aberrant 
promoter methylation partly explain their downregulation. For the MMSP 
assay purpose we judged ITGA9 to be better due to higher specificity. The 
possible role of ITGA9 and WNT7A as TSGs in NPC deserves further 
functional analysis 	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4. We developed an MMSP assay for NSCLC. In tissue derived DNA the 
Sensitivity and Specificity of detecting NSCLC were 87% and 94% 
respectively. Next step will be to apply the MMSP protocol on DNA from 
bronchoalveolar lavage fluid, sputum or even serum from lung cancer 
patients. 	  
There are now many different types of biomarkers with a potential to be used to detect 
cancer early by screening, to guide choice of and follow effects of treatment and to 
distinguish subtypes within one group of cancer. In addition to serum proteins and 
DNA with specific mutations, they include microRNAs and exosomes. Tumor specific 
methylated DNA should be added as another highly interesting type of biomarker, as 
aberrant DNA methylation can be one mechanism to silence TSGs and may as such 
appear very early during tumorigenesis. It has the advantage of being highly specific if 
the right marker gene is chosen and the molecules are relatively stable. As epigenetic 
reprogramming is a hallmark of cancer to be added there is a large spectrum of 
methylated genes/sequences to choose between in each type of cancer. From these it 
will be important to choose the most specific and informative markers. Individual 
epigenetic tumor markers have to be distinguished from those common to a tumor type. 
Novel high through put methods will provide large data sets to select candidate 
genes/sequences from, but these methods are yet too insensitive to be applied on small 
amounts of methylated DNA in body fluids. Issues of sensitivity still have to be 
resolved, and isolation, quality and storage of biological specimens are always 
important. Isolation of circulating tumor cells from blood combined with methylation 
profiling is an interesting possibility, as well as biotechnological improvements of 
assays to detect specific methylated sequences with high sensitivity. 
Like with any biomarkers, their usefulness has to be validated in large clinical studies, 
and it will be a challenge to extract those markers that will make it all the way to such 
studies. 
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